Sorrento Therapeutics Company Profile (NASDAQ:SRNE)

Analyst Ratings

Consensus Ratings for Sorrento Therapeutics (NASDAQ:SRNE) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.00 (365.89% upside)

Analysts' Ratings History for Sorrento Therapeutics (NASDAQ:SRNE)
Show:
DateFirmActionRatingPrice TargetActions
7/17/2016Rodman & RenshawReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/15/2016Brean CapitalReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2016FBR & CoLower Price TargetOutperform$21.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/7/2015HC WainwrightInitiated CoverageBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/3/2015MLV & Co.Initiated CoverageBuy$34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/15/2014AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Sorrento Therapeutics (NASDAQ:SRNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
11/16/2015Q315($0.03)$1.28 million$1.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.32)($0.27)$1.28 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/18/2014($0.34)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/23/2014($0.29)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sorrento Therapeutics (NASDAQ:SRNE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.52)($0.37)($0.45)
Q2 20161($0.15)($0.15)($0.15)
Q3 20161($0.15)($0.15)($0.15)
Q4 20161($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sorrento Therapeutics (NASDAQ:SRNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sorrento Therapeutics (NASDAQ:SRNE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/29/2016Patrick Soon-ShiongMajor ShareholderSell3,400$5.82$19,788.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2016Patrick Soon-ShiongMajor ShareholderSell6,901$5.85$40,370.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2016Patrick Soon-ShiongMajor ShareholderSell19,836$5.87$116,437.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2016Patrick Soon-ShiongMajor ShareholderSell53,764$6.14$330,110.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2016Patrick Soon-ShiongMajor ShareholderSell37,792$6.15$232,420.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016Patrick Soon-ShiongMajor ShareholderSell100,000$6.19$619,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2015Henry JiCEOBuy500$0.95$475.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2015Henry JiCEOBuy8,888$12.84$114,121.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015Henry JiCEOBuy8,888$13.08$116,255.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2014Henry JiCEOBuy5,999$4.83$28,975.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2014Henry JiCEOBuy4,000$4.56$18,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2014Henry JiCEOBuy3,000$4.53$13,590.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013Henry JiCEOBuy1,000$8.92$8,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2013Henry JiCEOBuy1,000$8.54$8,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2013Jaisim ShahDirectorBuy1,000$8.65$8,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/22/2013Henry JiCEOBuy1,000$8.47$8,470.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/22/2013Opko Health, Inc.Major ShareholderSell8,471$8.50$72,003.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2013George UyInsiderBuy3,000$8.36$25,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2013Opko Health, Inc.Major ShareholderSell4,269$8.53$36,414.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2013Opko Health, Inc.Major ShareholderSell17,062$8.75$149,292.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013George UyInsiderBuy2,031$8.61$17,486.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Henry JiCEOBuy2,000$8.59$17,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Jaisim ShahDirectorBuy1,000$9.00$9,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013Opko Health, Inc.Major ShareholderSell2,710$8.75$23,712.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2013Opko Health, Inc.Major ShareholderSell1,900$8.75$16,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2013Opko Health, Inc.Major ShareholderSell13,457$8.75$117,748.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/8/2013Opko Health, Inc.Major ShareholderSell2,000$8.75$17,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2013Opko Health, Inc.Major ShareholderSell120,380$9.03$1,087,031.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sorrento Therapeutics (NASDAQ:SRNE)
DateHeadline
07/25/16 10:57 AMSorrento Therapeutics, Inc. (NASDAQ:SRNE) increased 6.03%: Violin Memory, Inc. (NYSE:VMEM), Spirit AeroSystems ... - KC Register
07/23/16 10:22 AMChecking in on Stock Volatility for: Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - Engelwood Daily
07/23/16 10:22 AMSorrento Therapeutics Incorporated (NASDAQ:SRNE) Shorted Shares Decreased By 0.55% - Consumer Eagle
07/23/16 10:22 AMSorrento Therapeutics, Inc. (NASDAQ:SRNE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/23/16 10:22 AMStock Up Nicely This Week: Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - TGP
07/21/16 06:53 PMInvestor News: Lawsuit filed against certain directors of Sorrento Therapeutics Inc (NASDAQ:SRNE)
07/21/16 09:23 AMAfter Today's Huge Increase, Is Sorrento Therapeutics Inc's Near ... - Consumer Eagle
07/20/16 09:30 AMEquity Roundup: Stock Performance Focus on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - Press Telegraph
07/20/16 09:30 AMInvestor News: Lawsuit filed against certain directors of Sorrento Therapeutics Inc (NASDAQ:SRNE) - GroundReport
07/20/16 09:30 AMSorrento Therapeutics Inc Realized Volatility Hits Extreme Level - CML News
07/20/16 07:22 AMSorrento Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRNE-US : July 20, 2016 -
07/19/16 07:33 AMSorrento Therapeutics, Inc. (NASDAQ:SRNE) Expected To Post Sales Of $145.571 - Investor Newswire
07/18/16 11:01 AMOption Market: Sorrento Therapeutics Inc Risk Hits An Elevated Level - CML News
07/18/16 11:01 AMSorrento Therapeutics Incorporated (NASDAQ:SRNE) Sellers Increased By 0.61% Their Shorts - Consumer Eagle
07/18/16 11:01 AMNext Weeks Broker Price Targets For Sorrento Therapeutics, Inc. (SRNE) - Fiscal Standard
07/17/16 10:35 AMShares Moving Down on the Week: Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - Engelwood Daily
07/17/16 10:35 AMShares Experiencing a Downtrend: Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - TGP
07/15/16 11:49 AMSorrento Therapeutics, Inc. (NASDAQ:SRNE) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/13/16 06:55 PMLawsuit for Investors in Shares of Sorrento Therapeutics Inc (NASDAQ:SRNE) over Alleged Breaches of Fiduciary Duties by Certain Directors Filed
07/12/16 10:56 AMSorrento Therapeutics Incorporated (NASDAQ:SRNE) Shorted Shares Increased By 0.61% - Press Telegraph
07/12/16 10:56 AMSorrento Therapeutics (SRNE), Servier Enter Anti-PD-1 Antibody Licensing, Collaboration Agreement - StreetInsider.com
07/11/16 06:30 PMSorrento Therapeutics to Partner With French Pharma Servier
07/11/16 08:11 AMSORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S -
07/11/16 08:00 AMSorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercialization of Anti-PD-1 Antibody - [CNW Group] - Sorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercialization of Anti-PD-1 Antibody
07/09/16 05:53 PMBrokers Issue Average Price Target Of 24.25 On Sorrento Therapeutics, Inc. (SRNE) - Fiscal Standard
07/07/16 07:11 AMSorrento Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRNE-US : July 7, 2016 -
07/05/16 10:49 AMInvestors Alert: CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), Sorrento Therapeutics, Inc. (NASDAQ:SRNE ... - KC Register
07/04/16 05:38 PMSales of $145.571 expected for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - Investor Newswire
07/01/16 06:35 PMToday Sorrento Therapeutics Inc Stock Crashes - Engelwood Daily
07/01/16 03:16 PMSORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -
06/30/16 04:12 PMSORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/29/16 06:29 PMEquity Research and Technical Review on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - Press Telegraph
06/28/16 06:26 PMSorrento Therapeutics, Inc. (NASDAQ:SRNE) Yearly Sales Target At $145.571 - Investor Newswire
06/28/16 06:26 PMSorrento Therapeutics Incorporated (NASDAQ:SRNE) Shorted Shares Increased 0.61% After Market Selling - Engelwood Daily
06/27/16 06:26 PMNASDAQ:SRNE Stockholder Notice: Investigation of possible Wrongdoing at Sorrento Therapeutics Inc
06/24/16 06:37 PMSorrento Therapeutics, Inc. (NASDAQ:SRNE) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 06:36 PMRecently Issued Stock Ratings For Sorrento Therapeutics, Inc. (SRNE) - Fiscal Standard
06/24/16 04:28 PMBRIEF-Frejoy Investment Management reports 9.2 pct passive stake in Sorrento Therapeutics - * Frejoy Investment Management Co Ltd reports 9.2 percent passive stake in Sorrento Therapeutics Inc as of june 7, 2016 - SEC filing Source text: http://1.usa.gov/28TiETY Further company coverage:...
06/21/16 06:03 PMInvestor News: Investigation over potential Wrongdoing at Sorrento Therapeutics Inc (NASDAQ:SRNE)
06/20/16 08:02 AMInvestor News: Investigation over potential Wrongdoing at Sorrento Therapeutics Inc (NASDAQ:SRNE) - GroundReport
06/15/16 06:27 PMSorrento Therapeutics, Inc. (SRNE) Updated Price Targets - FTSE News
06/14/16 06:13 PMSorrento Therapeutics, Inc. (NASDAQ:SRNE) Yearly Sales Estimate At $145.571 - Investor Newswire
06/13/16 09:33 AMInvestigation for Investors Who Hold Shares of Sorrento Therapeutics Inc (NASDAQ:SRNE) Announced
06/08/16 06:08 AMSorrento Closes $150 Million Private Placement Investments - [at noodls] - SAN DIEGO, June 8, 2016/PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; 'Sorrento'), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other ...
06/07/16 06:50 PMSorrento Therapeutics Signs Deal with Chinese Pharmaceutical Co.
06/07/16 08:18 AMSorrento and 3SBio Announce CAR-T Joint Venture in China - [at noodls] - SAN DIEGO, June 7, 2016/PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ('Sorrento'), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other ...
06/06/16 03:50 PMSORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equi -
06/04/16 09:34 AMSorrento Therapeutics Inc. (SRNE): Wildcat Capital Management Growing Impatient With Lack of Disclosure, Repeats ... - Insider Monkey (blog)
06/03/16 08:19 PMSorrento Therapeutics Inc. (SRNE): Wildcat Capital Management Growing Impatient With Lack of Disclosure, Repeats Demands -
06/03/16 07:13 PMStock Review and Earnings Check on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - HNN

Social

About Sorrento Therapeutics

Sorrento Therapeutics logoSorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SRNE
  • CUSIP:
Key Metrics:
  • Previous Close: $6.01
  • 50 Day Moving Average: $6.15
  • 200 Day Moving Average: $6.08
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $246.10M
  • Beta: 1.58
  • Current Year EPS Consensus Estimate: $-0.93 EPS
  • Next Year EPS Consensus Estimate: $-0.51 EPS
Additional Links:
Sorrento Therapeutics (NASDAQ:SRNE) Chart for Tuesday, July, 26, 2016